171 related articles for article (PubMed ID: 14997235)
1. Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies.
Rayner B; Jaeger B; Verboom CN; Pascoe M
Cardiovasc J S Afr; 2004; 15(1):32-7. PubMed ID: 14997235
[TBL] [Abstract][Full Text] [Related]
2. Clinical profile of eprosartan.
Puig JG; López MA; Bueso TS; Bernardino JI; Jiménez RT;
Cardiovasc Drugs Ther; 2002 Dec; 16(6):543-9. PubMed ID: 12766389
[TBL] [Abstract][Full Text] [Related]
3. Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
Hollenberg NK
Curr Hypertens Rep; 2001 Sep; 3 Suppl 1():S25-8. PubMed ID: 11580885
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin blockade with eprosartan: vascular and functional implications.
Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
[TBL] [Abstract][Full Text] [Related]
5. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
de la Sierra A; Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
[TBL] [Abstract][Full Text] [Related]
6. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
[TBL] [Abstract][Full Text] [Related]
7. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
[TBL] [Abstract][Full Text] [Related]
8. Eprosartan dual action offers clinical benefit for elderly and overweight hypertensives.
Cardiovasc J S Afr; 2004; 15(2):91-2. PubMed ID: 15148545
[No Abstract] [Full Text] [Related]
9. Eprosartan for the treatment of hypertension.
Ruilope L; Jäger B
Expert Opin Pharmacother; 2003 Jan; 4(1):107-14. PubMed ID: 12517247
[TBL] [Abstract][Full Text] [Related]
10. The clinical profile of the angiotensin II receptor blocker eprosartan.
Hedner T
J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
[TBL] [Abstract][Full Text] [Related]
11. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B
Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
[TBL] [Abstract][Full Text] [Related]
12. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
Rupp H
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S25-9. PubMed ID: 18093411
[TBL] [Abstract][Full Text] [Related]
13. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
14. Management of hypertension: the advent of a new angiotensin II receptor antagonist.
Hedner T
J Hypertens Suppl; 1999 Jun; 17(2):S21-5. PubMed ID: 10465063
[TBL] [Abstract][Full Text] [Related]
15. Eprosartan: a review of its use in the management of hypertension.
Robins GW; Scott LJ
Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
[TBL] [Abstract][Full Text] [Related]
16. Clinical profile of eprosartan: a different angiotensin II receptor blocker.
Blankestijn PJ; Rupp H
Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):253-7. PubMed ID: 18855637
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Dowlatshahi D; Hill MD
Expert Rev Cardiovasc Ther; 2009 May; 7(5):459-64. PubMed ID: 19419253
[TBL] [Abstract][Full Text] [Related]
18. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
Leu HB; Charng MJ; Ding PY
Jpn Heart J; 2004 Jul; 45(4):623-35. PubMed ID: 15353873
[TBL] [Abstract][Full Text] [Related]
19. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
20. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Ram CV; Rudmann MA
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
